FLT3
39 programs · 39 companies
Programs
39
Companies
39
Active Trials
35
Targeting FLT3
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | PVBladder Ca | |
| Sotorapivir | Moderna | Approved | PNH | |
| Nidaratamab | Exelixis | Phase 3 | AsthmaMM | |
| Zanumavacamten | Iovance | Phase 2 | CMLMigraine | |
| RAR-440 | Ultragenyx | Phase 2 | MG | |
| Motasacituzumab | Olema | NDA/BLA | ACC | |
| Tixafotisoran | Mineralys | Phase 3 | NBGastric Ca | |
| Capirelsin | Y-mAbs | Phase 2 | FSGSBladder Ca | |
| MAY-IIT-936 | Mayo Clinic | Phase 3 | GA | |
| NAT-IIT-209 | Natl Cancer Ctr Japan | Phase 2/3 | GIST | |
| Datocilimab | Erasca | Approved | Cervical CaCTCL | |
| ARC-6205 | ARCH Venture | NDA/BLA | PTSD | |
| KAL-3824 | Kala Pharma | Phase 1/2 | ASNASH | |
| Tirainavolisib | ContraFect (Phibro) | Phase 3 | Parkinson's | |
| TUR-1584 | Turning Point (BMS) | Phase 2/3 | GACSU | |
| Ivocapivasertib | Achilles Therapeutics | Phase 1 | Endometrial CaFTD | |
| ZYN-1124 | Zynerba Pharma | NDA/BLA | HNSCC | |
| Suraosocimab | Immunomedics (Gilead) | Phase 1/2 | DravetCeliac | |
| Elrafotisoran | PharmaCyte Biotech | Phase 3 | ALSADPKD | |
| Motanaritide | Second Sight | Approved | DLBCLAML | |
| Adagrazasiran | Corvus Pharma | Phase 3 | SchizophreniaParkinson's | |
| Tiranaritide | Heron Therapeutics | Preclinical | BCCPsoriasis | |
| RLY-2544 | Rallybio | Preclinical | CRCPsoriasis | |
| Surazumab | IMV (renamed Immunovaccine) | Preclinical | MMADPKD | |
| Daralucimab | Rain (Qilu) | Phase 2/3 | SLE | |
| Mirirasimod | Livzon Pharma | Approved | CMLAML | |
| Tiratinib | Harmony Bio | Preclinical | Endometrial CaBCC | |
| Sovaratamab | Transgene | Phase 2/3 | CeliacCKD | |
| TRI-2954 | Trillium (Pfizer) | Approved | DravetT2D | |
| Darafutibatinib | Biophytis | Approved | ETIgAN | |
| Polaratamab | Helixmith | Phase 2 | ETPompe | |
| GRA-2645 | Granules India | Phase 2 | GBMNASH | |
| SIA-2247 | Siam Bioscience | Preclinical | CTCLLGS | |
| ASA-IIT-449 | Asan Medical Center | Approved | Hemophilia A | |
| Fixacagene | Agilent Technologies | NDA/BLA | CLL | |
| ZHE-9252 | Zhejiang Jiuzi | Phase 3 | Bladder Ca | |
| Lisoderotide | Abbisko Therapeutics | Phase 2 | Schizophrenia | |
| Rimarelsin | Y Biologics | Phase 3 | CRC | |
| Gozeosocimab | GenNBio | Phase 1/2 | SCDSchizophrenia |